Abstract
Sepsis remains a common cause of death in the intensive care units worldwide. However, in the last decade a significant development could be noticed in sepsis research regarding diagnostic markers that can help the physicians to recognize the disease in the early phase, which is the clue of the successful treatment of sepsis. This development provided the identification of new molecules and structures (i.e. cytokins, cell surface markers, receptors) that are potential biomarkers of sepsis in the clinical settings. Besides, the advance in the understanding of the pathophysiologic, immunologic and biochemical pathway of sepsis has made the way for assignment of new drug targets in the therapy of sepsis. This review aims to provide a summary about these novelties regarding our knowledge about sepsis published in the medical literature recently. We will describe the presumed pathophysiological role and diagnostic value of sepsis markers that are used even more widely in the clinical practice (i.e. procalcitonin, IL-6), summarize the data regarding the sepsis marker candidates that are investigated in some initial study (i.e. matrix metalloproteinases, microRNA fingerprints), and we will discuss substances that may be specific markers for certain organ failures related to sepsis (i.e. neutrophil gelatinase-derived lipocalin in acute renal failure). Furthermore, we will review the mediators of the immuno-inflammatory cascade in sepsis concerning their potential applicability as therapeutic targets in the treatment of this often lethal disease. In addition, we present some insights into the identification of genetic markers of sepsis.
Keywords: Sepsis, septic shock, marker, diagnosis, prognosis, organ failure, therapy, therapeutic target, procalcitonin, interleukin-6, matrix metalloproteinase, neutrophil gelatinase-associated lipocalin, brain type natriuretic peptide, soluble triggering receptor expressed on myeloid cells
Current Medicinal Chemistry
Title: Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets
Volume: 18 Issue: 21
Author(s): B. Ivady, B. J. Beres and D. Szabo
Affiliation:
Keywords: Sepsis, septic shock, marker, diagnosis, prognosis, organ failure, therapy, therapeutic target, procalcitonin, interleukin-6, matrix metalloproteinase, neutrophil gelatinase-associated lipocalin, brain type natriuretic peptide, soluble triggering receptor expressed on myeloid cells
Abstract: Sepsis remains a common cause of death in the intensive care units worldwide. However, in the last decade a significant development could be noticed in sepsis research regarding diagnostic markers that can help the physicians to recognize the disease in the early phase, which is the clue of the successful treatment of sepsis. This development provided the identification of new molecules and structures (i.e. cytokins, cell surface markers, receptors) that are potential biomarkers of sepsis in the clinical settings. Besides, the advance in the understanding of the pathophysiologic, immunologic and biochemical pathway of sepsis has made the way for assignment of new drug targets in the therapy of sepsis. This review aims to provide a summary about these novelties regarding our knowledge about sepsis published in the medical literature recently. We will describe the presumed pathophysiological role and diagnostic value of sepsis markers that are used even more widely in the clinical practice (i.e. procalcitonin, IL-6), summarize the data regarding the sepsis marker candidates that are investigated in some initial study (i.e. matrix metalloproteinases, microRNA fingerprints), and we will discuss substances that may be specific markers for certain organ failures related to sepsis (i.e. neutrophil gelatinase-derived lipocalin in acute renal failure). Furthermore, we will review the mediators of the immuno-inflammatory cascade in sepsis concerning their potential applicability as therapeutic targets in the treatment of this often lethal disease. In addition, we present some insights into the identification of genetic markers of sepsis.
Export Options
About this article
Cite this article as:
Ivady B., J. Beres B. and Szabo D., Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets, Current Medicinal Chemistry 2011; 18 (21) . https://dx.doi.org/10.2174/092986711796391598
DOI https://dx.doi.org/10.2174/092986711796391598 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets miRNA-Dependent Activation of mRNA Translation
MicroRNA Role of Bradykinin in the Regulation of Endothelial Nitric Oxide Synthase Expression by Cardiovascular Drugs
Current Pharmaceutical Design Editorial [Hot topic: MDMA (Ecstasy) Toxicity: Pharmacokinetic, Metabolism, Cell Response and Pathological Consequences (Guest Editor: Vittorio Fineschi)]
Current Pharmaceutical Biotechnology Cathinone Neurotoxicity (“The “3Ms”)
Current Neuropharmacology Effect of Hypoxia on Cytochrome P450 Activity and Expression
Current Drug Metabolism Vitamin D and Cardiovascular Disease
Current Vascular Pharmacology Phytocompounds as Potential Agents to Treat Obesity-Cardiovascular Ailments
Cardiovascular & Hematological Agents in Medicinal Chemistry Design and Synthesis of an Aniline Derivative with Biological Activity on Heart Failure
Combinatorial Chemistry & High Throughput Screening Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals How to Advise Aspirin Use in Patients Who Need NSAIDs
Current Pharmaceutical Design Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?
Current Drug Targets In vitro and in vivo Evaluation of Antitumor Drug-Loaded Aptamer Targeted Single-Walled Carbon Nanotubes System
Current Pharmaceutical Biotechnology Thrombus Extraction Catheters vs. Angiojet Rheolytic Thrombectomy in Thrombotic Lesions/SV Grafts
Current Cardiology Reviews Targeting STAT1 in Both Cancer and Insulin Resistance Diseases
Current Protein & Peptide Science Diabetic Heart and the Cardiovascular Surgeon
Cardiovascular & Hematological Disorders-Drug Targets Wharton's Jelly Mesenchymal Stem Cell Response on Chitosan-graft-poly (ε-caprolactone) Copolymer for Myocardium Tissue Engineering
Current Pharmaceutical Design Replicative Senescence: The Final Stage of Memory T Cell Differentiation?
Current HIV Research Ezetimibe and Vascular Endothelial Function
Current Vascular Pharmacology